Breakthrough Acute HIV Infections among Pre-Exposure Prophylaxis Users with High Adherence: A Narrative Review

被引:2
作者
Moschese, Davide [1 ]
Lazzarin, Samuel [2 ,3 ]
Colombo, Martina Laura [2 ,3 ]
Caruso, Francesco [2 ,4 ]
Giacomelli, Andrea [2 ,3 ]
Antinori, Spinello [2 ,3 ]
Gori, Andrea [1 ,2 ,4 ,5 ]
机构
[1] Luigi Sacco Hosp, Div Infect Dis 1, ASST Fatebenefratelli Sacco, I-20157 Milan, Italy
[2] Univ Milan, Dept Biomed & Clin Sci, I-20133 Milan, Italy
[3] Luigi Sacco Hosp, Infect Dis Unit 3, ASST Fatebenefratelli Sacco, I-20157 Milan, Italy
[4] Luigi Sacco Hosp, Infect Dis Unit 2, ASST Fatebenefratelli Sacco, I-20157 Milan, Italy
[5] Univ Milan, Ctr Multidisciplinary Res Hlth Sci MACH, Milan, Italy
来源
VIRUSES-BASEL | 2024年 / 16卷 / 06期
关键词
HIV; primary HIV; PrEP; failure; adherence; IMMUNODEFICIENCY-VIRUS; DRUG-RESISTANCE; ANTIRETROVIRAL PROPHYLAXIS; TRANSGENDER WOMEN; DOUBLE-BLIND; MEN; TENOFOVIR; SEX; PREVENTION; CABOTEGRAVIR;
D O I
10.3390/v16060951
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Pre-exposure prophylaxis (PrEP) is a pivotal intervention among HIV prevention strategies. We aimed to narratively revise the topic of HIV acute infection in the setting of PrEP exposure with a focus on diagnostic options, clinical features, and future PrEP perspectives, with a particular focus on users with high adherence to PrEP. We searched the main databases (PubMed, Embase, and Scopus) with the keywords "PrEP" or "Pre-Exposure Prophylaxis" and "HIV" or "PLWH" and "breakthrough" or "acute infection" or "primary infection". We included all randomized clinical trials and non-experimental studies (both case reports and observational studies) ever published. In the present narrative review, we revise the diagnostic challenges related to HIV diagnosis in the setting of PrEP and the clinical characteristics and symptoms of breakthrough infections. We discuss the management of acute HIV infection during PrEP and the new challenges that arise from the use of long-acting drugs for PrEP. Our review underlines that although extremely rare, HIV seroconversions are still possible during PrEP, even in a context of high adherence. Efforts to promptly identify these events must be included in the PrEP follow-up in order to minimize the chance of overlooked HIV breakthrough infections and thus exposure to suboptimal concentrations of antiretrovirals.
引用
收藏
页数:19
相关论文
共 89 条
[1]   The contemporary immunoassays for HIV diagnosis: a concise overview [J].
Abdullah ;
Din, Misbahud ;
Waris, Abdul ;
Khan, Muddasir ;
Ali, Sajjad ;
Muhammad, Riaz ;
Salman, Muhammad .
ASIAN BIOMEDICINE, 2023, 17 (01) :3-12
[2]   Primary HIV-1 infection in users of pre-exposure prophylaxis [J].
Ambrosioni, Juan ;
Petit, Elisa ;
Liegeon, Geoffroy ;
Laguno, Montserrat ;
Miro, Jose M. .
LANCET HIV, 2021, 8 (03) :e166-e174
[3]   HIV DNA Set Point is Rapidly Established in Acute HIV Infection and Dramatically Reduced by Early ART [J].
Ananworanich, Jintanat ;
Chomont, Nicolas ;
Eller, Leigh Ann ;
Kroon, Eugene ;
Tovanabutra, Sodsai ;
Bose, Meera ;
Nau, Martin ;
Fletcher, James L. K. ;
Tipsuk, Somporn ;
Vandergeeten, Claire ;
O'Connell, Robert J. ;
Pinyakorn, Suteeraporn ;
Michael, Nelson ;
Phanuphak, Nittaya ;
Robb, Merlin L. .
EBIOMEDICINE, 2016, 11 :68-72
[4]  
[Anonymous], 2022, IN DANGER: UNAIDS Global AIDS Update 2022
[5]  
[Anonymous], 2023, EACS Guidelines version 12.0
[6]  
[Anonymous], 2018, Preexposure Prophylaxis for the Prevention of HIV Infection in the United States - 2017 Update - A Clinical Practice Guideline
[7]  
[Anonymous], 2018, WHO Implementation Tool for Pre-Exposure Prophylaxis (PrEP) of HIV Infection: Adolescents and Young Adults [Internet]
[8]  
[Anonymous], Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents
[9]   Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women [J].
Baeten, J. M. ;
Donnell, D. ;
Ndase, P. ;
Mugo, N. R. ;
Campbell, J. D. ;
Wangisi, J. ;
Tappero, J. W. ;
Bukusi, E. A. ;
Cohen, C. R. ;
Katabira, E. ;
Ronald, A. ;
Tumwesigye, E. ;
Were, E. ;
Fife, K. H. ;
Kiarie, J. ;
Farquhar, C. ;
John-Stewart, G. ;
Kakia, A. ;
Odoyo, J. ;
Mucunguzi, A. ;
Nakku-Joloba, E. ;
Twesigye, R. ;
Ngure, K. ;
Apaka, C. ;
Tamooh, H. ;
Gabona, F. ;
Mujugira, A. ;
Panteleeff, D. ;
Thomas, K. K. ;
Kidoguchi, L. ;
Krows, M. ;
Revall, J. ;
Morrison, S. ;
Haugen, H. ;
Emmanuel-Ogier, M. ;
Ondrejcek, L. ;
Coombs, R. W. ;
Frenkel, L. ;
Hendrix, C. ;
Bumpus, N. N. ;
Bangsberg, D. ;
Haberer, J. E. ;
Stevens, W. S. ;
Lingappa, J. R. ;
Celum, C. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (05) :399-410
[10]   Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial [J].
Baeten, Jared M. ;
Donnell, Deborah ;
Mugo, Nelly R. ;
Ndase, Patrick ;
Thomas, Katherine K. ;
Campbell, James D. ;
Wangisi, Jonathan ;
Tappero, Jordan W. ;
Bukusi, Elizabeth A. ;
Cohen, Craig R. ;
Katabira, Elly ;
Ronald, Allan ;
Tumwesigye, Elioda ;
Were, Edwin ;
Fife, Kenneth H. ;
Kiarie, James ;
Farquhar, Carey ;
John-Stewart, Grace ;
Kidoguchi, Lara ;
Coombs, Robert W. ;
Hendrix, Craig ;
Marzinke, Mark A. ;
Frenkel, Lisa ;
Haberer, Jessica E. ;
Bangsberg, David ;
Celum, Connie .
LANCET INFECTIOUS DISEASES, 2014, 14 (11) :1055-1064